•
Helixworks Technologies • 8m
Yikes! Fair skepticism—biotech IPOs can be brutal for retail investors. Molbio’s timing is definitely interesting, but I think the underlying tech has real potential beyond the COVID spike. That said, the company wouldn’t be at this stage without the pandemic-driven demand. I’m curious to see if they can scale like Cepheid or if this is just a well-timed cash-out. Would a post-IPO correction change your mind, or are you completely out on biotech?
•
Helixworks Technologies • 8m
From ₹51 Cr to ₹1,272 Cr in a year—this Indian biotech’s revenue chart is insane. 💰 Molbio is going public targeting ₹22,000–24,000 Cr valuation. IPO expected in November 2025, raising ₹2,200–2,400 Cr. 🔬 Their Truenat platform, is a battery-power
See More
•
Techsaga Corporations • 1y
Kya aap bhi toh doomscrolling nahi karte??------ . --- Pehle Bookmark then Socho ------->> . Understanding Doomscrolling: Key Facts and Stats 1. What is Doomscrolling? - 📱 Definition: Doomscrolling is the habit of continuously consuming negative
See More
We builds future • 3m
Is India in an Innovation Drought? India’s startup ecosystem has become a global force, fueled by entrepreneurial energy, increasing valuations, and international attention. But beyond the optimism, challenges remain. To sustain its momentum, India
See MoreFounder Snippetz Lab... • 2m
96% “sold-out” projects. ₹4.72 Cr average price. 60% investor-driven demand. Looks like India’s hottest housing market, right? Think again. Gurugram real estate market seems to be booming on paper - but in reality, it's basically an ecosystem whic
See More
Download the medial app to read full posts, comements and news.